Medpace: 3 Key Takeaways for Long-Term Investors
On its third-quarter 2026 earnings call, held on Oct. 22, 2026, Medpace (NASDAQ:MEDP) reported a record number of net new business awards for the period. For long-term investors, contract win rates and cancellation patterns offer crucial signals about core demand in clinical trial management. Three things management said stand out. Client demand remained high, driving quarterly contract awards entering backlog, or contracted work not yet performed, to unprecedented levels. Project cancellations now stem primarily from clinical trial safety signals and efficacy results rather than client capital constraints. Continue reading